{"id":4187,"date":"2024-02-08T06:30:31","date_gmt":"2024-02-08T11:30:31","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/"},"modified":"2026-09-24T00:05:52","modified_gmt":"2026-09-24T04:05:52","slug":"gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/","title":{"rendered":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"author":4,"featured_media":4189,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,80],"post-year":[],"class_list":["post-4187","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Please open this post to complete the access confirmation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-08T11:30:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png\" \/>\n\t<meta property=\"og:image:width\" content=\"959\" \/>\n\t<meta property=\"og:image:height\" content=\"458\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital\",\"datePublished\":\"2024-02-08T11:30:31+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/\"},\"wordCount\":2586,\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Table-CP.png\",\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/\",\"name\":\"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Table-CP.png\",\"datePublished\":\"2024-02-08T11:30:31+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Table-CP.png\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Table-CP.png\",\"width\":959,\"height\":458},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/02\\\/08\\\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics","og_description":"Please open this post to complete the access confirmation.","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/","og_site_name":"GenSight Biologics","article_published_time":"2024-02-08T11:30:31+00:00","article_modified_time":"2026-09-24T04:05:52+00:00","og_image":[{"width":959,"height":458,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png","type":"image\/png"}],"author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital","datePublished":"2024-02-08T11:30:31+00:00","dateModified":"2026-09-24T04:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/"},"wordCount":2586,"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png","articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/","name":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#primaryimage"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png","datePublished":"2024-02-08T11:30:31+00:00","dateModified":"2026-09-24T04:05:52+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#primaryimage","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Table-CP.png","width":959,"height":458},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/02\/08\/gensight-biologics-annonce-la-finalisation-dune-augmentation-de-capital-de-5-millions-deuros-souscrite-par-sofinnova-partners-invus-upmc-enterprises-et-heights-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce la finalisation d\u2019une augmentation de capital de 5 millions d\u2019euros souscrite par Sofinnova Partners, Invus, UPMC Enterprises et Heights Capital"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4187"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4187\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media\/4189"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4187"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4187"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4187"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4187"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}